Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03067181 · ClinicalTrials.gov registry record · Phase 3

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

A Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor, sponsored by Children's Oncology Group.

Recruiting
Registry status
Phase 3
Development phase
1,780
Enrollment target
20
Study locations

NCT03067181: Recruiting Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor, sponsored by Children's Oncology Group.

NCT03067181 is a Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 1,780 participants, above the 254-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (601% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03067181, a Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor, is actively recruiting participants, sponsored by Children's Oncology Group.

RECRUITING
Registry status
Phase 3
Development phase
1,780 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Primary Outcome

The time from study entry to the date of death, or date of last contact and ascertained as alive, whichever comes first.

Interventions

  • DRUG Carboplatin
  • PROCEDURE Biospecimen Collection
  • PROCEDURE Biopsy Procedure
  • OTHER Best Practice
  • BIOLOGICAL Bleomycin Sulfate

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage

Arizona

  • Kingman Regional Medical Center - Kingman
  • Banner Children's at Desert - Mesa
  • Cancer Center at Saint Joseph's - Phoenix
  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson
  • University of Arizona Cancer Center-North Campus - Tucson

Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • Arkansas Children's Hospital - Little Rock
  • CARTI Cancer Center - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Alabama

  • Children's Hospital of Alabama - Birmingham
  • USA Health Strada Patient Care Center - Mobile

Trial Details

FieldValue
Enrollment Target 1,780 participants
Start Date 2017-05-25
Est. Completion 2027-06-30
Phase Phase 3
Children's Oncology Group

342 total trials

What NCT03067181 shows while recruiting

NCT03067181 is an interventional study that assigns participants to a tested intervention. Its 1,780 participants enrollment target places it among the larger protocols in the corpus, above the 254-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (601% higher).

The record links to 10 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT03067181 names 20 study sites across 4 states, led by Alaska, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT03067181 about?

NCT03067181 is a clinical study titled "Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors". This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such...

What is the current status of trial NCT03067181?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,780 participants. The study started on 2017-05-25. Estimated completion is 2027-06-30.

What conditions does trial NCT03067181 study?

This clinical trial studies the following conditions: Germ Cell Tumor, Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma.

What interventions are being tested in trial NCT03067181?

The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Biopsy Procedure (PROCEDURE), Best Practice (OTHER), Bleomycin Sulfate (BIOLOGICAL).

Who is sponsoring clinical trial NCT03067181?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03067181 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Germ Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03067181's enrollment target sits among peer trials

1,780 1st of 19 higher than 19 of 19 other Germ Cell Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06526650 · 1,780 participants · NA

    'Ai Pono Cooking Demonstrations

  • NCT05770570 · 1,785 participants · Phase 2

    Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

  • NCT06239688 · 1,764 participants · NA

    Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce

  • NCT03630055 · 1,800 participants · Phase 3

    Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03067181, the US trial registry maintained by the National Library of Medicine. NCT03067181 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.